Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
- 30 September 2004
- journal article
- review article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 72 (3) , 257-266
- https://doi.org/10.1016/j.radonc.2004.07.007
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLCInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancerInternational Journal of Cancer, 2003
- Ultrafractionation in human malignant glioma xenograftsInternational Journal of Cancer, 2003
- Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?Journal of Clinical Oncology, 2003
- 58 oral Inhibition of AKT/ protein kinase b but not mitogen activated protein kinase/ ERK modulates radiation response by EGFR antagonistRadiotherapy and Oncology, 2003
- Localizing the EGF receptorNature Cell Biology, 2002
- EGF receptors as transcription factors: ridiculous or sublime?Nature Cell Biology, 2001
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy & Radiopharmaceuticals, 1999